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Work over the past 30 yr has resulted in a greater 
understanding of the biology and therapeutic 
  application of human stem cells in human 
  malignancies. The use of stem cell transplantation 
is an important tool in the treatment of several 
hematologic (1) and nonhematologic (2, 3) 
  malignancies. In contrast, several recent studies 
have suggested that stem and progenitor cells may 
be direct cellular targets of the genetic alterations 
leading to tumor formation as well as important 
contributors to the maintenance of human  cancers 
(4–6). In addition, other recent studies have 
altered the perception of the stromal cells that 
  surround epithelial tumors from being innocent 
bystanders in the neoplastic process to being a cell 
type that actively promotes the growth of the 
  adjacent transformed cells (7–11). However, the 
eff  ect of human mesenchymal stem cells (MSCs), 
the stromal progenitor stem cells found within 
the bone marrow, on the growth of human 
  tumors is not well understood.
The cell population known as MSCs are 
usually isolated from the mononuclear fraction 
of a bone marrow aspirate, which is then de-
pleted of CD45+ cells and subsequently isolated 
as the cell population that adheres to plastic tis-
sue culture dishes (12). MSCs can proliferate 
for many passages in culture and have the abil-
ity to give rise to several diff  erentiated cell types 
(13). MSCs have several properties that make 
them an attractive choice as a cell therapeutic 
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Emerging evidence suggests that both human stem cells and mature stromal cells can play 
an important role in the development and growth of human malignancies. In contrast to 
these tumor-promoting properties, we observed that in an in vivo model of Kaposi’s sar-
coma (KS), intravenously (i.v.) injected human mesenchymal stem cells (MSCs) home to 
sites of tumorigenesis and potently inhibit tumor growth. We further show that human 
MSCs can inhibit the in vitro activation of the Akt protein kinase within some but not all 
tumor and primary cell lines. The inhibition of Akt activity requires the MSCs to make 
direct cell–cell contact and can be inhibited by a neutralizing antibody against E-cadherin. 
We further demonstrate that in vivo, Akt activation within KS cells is potently down-
regulated in areas adjacent to MSC infi  ltration. Finally, the in vivo tumor-suppressive effects 
of MSCs correlates with their ability to inhibit target cell Akt activity, and KS tumors 
engineered to express a constitutively activated Akt construct are no longer sensitive 
to i.v. MSC administration. These results suggest that in contrast to other stem cells or 
normal stromal cells, MSCs possess intrinsic antineoplastic properties and that this stem 
cell population might be of particular utility for treating those human malignancies char-
acterized by dysregulated Akt.
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agent (14). They are easily obtained from a simple bone mar-
row aspirate that can be readily expanded to hundreds of mil-
lions of cells. MSCs also appear to have the ability to home to 
sites of tissue injury (15, 16). MSCs are easily transfectable, 
allowing for easy ex vivo modifi  cation. Finally, MSCs appear 
to be relatively nonimmunogenic (17), although the mecha-
nism of their immune privilege is not well understood and is 
a subject of intense study (18, 19).
Because of these properties, MSCs have considerable 
therapeutic potential in several disease processes, including 
cardiovascular disease (20), as well as in the treatment of 
  human malignancies (21). To explore the role of MSCs on 
tumorigenesis, we studied the eff  ects of human MSCs on 
Kaposi’s sarcoma (KS), a highly infl  ammatory angiogenic 
  tumor. KS is the most common AIDS-related malignancy 
(22, 23) and is characterized by multiple cutaneous and visceral 
vascular lesions in aff  ected patients. Propagation of KS is de-
pendent on proinfl  ammatory cytokines, angiogenic   factors, 
and adhesion molecule expression, all of which promote KS 
pathogenesis through both paracrine and autocrine mechanisms
(24). The production of many of these components is initiated 
by human herpes virus 8 infection, a necessary factor in KS 
pathogenesis (25, 26).
Based on the previous studies implicating stem cells and 
stromal support cells in the neoplastic process (4–11), we an-
ticipated that transplanted MSCs would accelerate the growth 
of tumors in vivo. In fact, some studies suggest that MSCs 
may represent a precursor to tumorigenic cells (27, 28). In 
addition, another study suggests that through their immune 
suppressive eff  ects, transplanted MSCs may enhance tumor 
growth in vivo (19). Furthermore, MSCs produce proangio-
genic cytokines and have been shown to enhance blood ves-
sel growth in several studies of chronic limb ischemia (29–31). 
Surprisingly, as described in this study, we found that MSCs 
can instead exert a profound antitumorigenic eff  ect  that 
  appears to be mediated by a contact-dependent inhibition 
of Akt activity.
RESULTS
i.v. injected human MSCs home to KS tumors in vivo
Human MSCs were obtained from several young, healthy 
donors and were pooled for use in all experiments. We ex-
tensively characterized these cells to show that they expressed 
the characteristic cell surface markers and produced the cyto-
kines typical of human MSCs (see Figs. S1 and S2, available at 
http://www.jem.org/cgi/content/full/jem.20051921/DC1). 
In particular, we observed that human MSCs produce high 
levels of proangiogenic cytokines in vitro.
Because previous studies have suggested that mature stro-
mal cells promote tumorigenesis through local paracrine ef-
fects (8, 9), we found it necessary to determine whether i.v. 
injected human MSCs could home to KS tumors in vivo. 
Previous studies suggest that systemically infused MSCs have 
the ability to home to sites of active tumorigenesis (21, 32). 
To test this in our model, on day 0, 4 × 106 human MSCs 
were injected i.v. into the tail vein of an athymic nude mouse. 
On the same day, 5 × 106 KS cells were implanted subcuta-
neously into the right fl  ank of the same mouse. To track the 
distribution of the MSCs within the mouse over time, we la-
beled the MSCs with superparamagnetic iron oxide particles, 
which allows for in vivo tracking of the cells by magnetic 
resonance imaging (MRI) by producing a characteristic hy-
pointense area resulting in a signal void within the MRI 
  image. A similar approach has been previously demonstrated 
to eff  ectively track the in vivo location of MSCs without the 
alteration of cellular function (33, 34). We also labeled the 
MSCs with a conjugated fl  uorophore (CM-DiI) to allow for 
easy identifi  cation in histopathological sections.
MRI of the subcutaneous fl  ank tumor demonstrated evi-
dence for the localization of iron oxide–labeled MSCs, which 
were indicated by small focal hypointense areas around the 
  tumor (Fig. 1 A).  These eff  ects were observed as early as 48 h 
after tumor implantation. Labeled MSCs were imaged with 
 100-μm in-plane resolution and 350-μm slice thickness. 
Over time, the hypointense MRI eff  ect became more pro-
nounced at the tumor periphery (Fig. 1 A). We also performed 
total body MRI of mice at 50-μm resolution in three dimen-
sions to evaluate all of the major organs and bone marrow 
(Fig. S3, available at http://www.jem.org/cgi/content/full/
jem.20051921/DC1). In both tumor-bearing and non–tumor-
bearing mice, we only observed extensive regions of a signal 
void, which are indicative of labeled MSCs, in the reticuloen-
dothelial system and within the lungs. We did not observe ap-
preciable numbers of MSCs in other highly vascular tissues, 
including the heart, brain, kidney, and skeletal muscle.
To confi  rm that the MRI fi  ndings represented the pres-
ence of iron-labeled MSCs within the tumors, we examined 
the excised tumors with fl  uorescence microscopy to look for 
the presence of the red fl  uorochrome CM-DiI. At day 2, la-
beled MSCs were seen diff  usely distributed throughout the 
densely cellular KS tumor (Fig. 1 B). At higher magnifi  ca-
tion, MSCs within KS tumors appeared to maintain the elon-
gated, fi  broblast-like appearance that they adopt in culture 
(Fig. 1 C). At day 5, we still could observe numerous MSCs 
within the center of the tumor, particularly around what ap-
peared to be acellular and necrotic areas (Fig. 1 D). By day 7, 
the overall number of MSCs within the tumor had dimin-
ished by almost threefold (day 2 vs. day 7; 47 cells/high 
power fi  eld ± 11 vs. 17 cells/high power fi  eld ± 10; P < 
0.001; n = 3 for each group). MSC homing to KS tumors 
maintained the spindle-shaped morphology that they adopted 
in culture, and these CM-Dil–positive cells showed no evi-
dence of diff  erentiation along myeloid or hematopoietic cell 
lineages, as assessed by the lack of expression of CD33, CD34, 
and myeloperoxidase, whereas the vast majority of MSCs 
maintained the expression of CD44 (unpublished data).
Human MSCs inhibit the growth of KS tumors 
in a dose-dependent manner
We next sought to assess the eff  ects of i.v. injected hu-
man MSCs on in vivo KS tumor growth. Surprisingly, as 
demonstrated in Fig. 2 A, a single dose of 4 × 106 MSCs that JEM VOL. 203, May 15, 2006  1237
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was administered i.v. coincident with KS tumor implantation 
resulted in a >50% decrease in KS tumor size (Fig. 2 A). 
Analysis of mean (Fig. 2 B) and individual tumor growth 
curves demonstrates the robustness of this eff  ect (Fig. 2 C). 
To determine whether the observed eff  ect on KS tumorigen-
esis represented a nonspecifi  c response to i.v. injection of 
  human cells in our athymic nude mouse model of KS, we 
performed similar experiments using infused human umbili-
cal vein endothelial cells (HUVECs), which express similar 
levels of MHC class I and II compared with human MSCs 
(unpublished data). As noted in Fig. 2 D, we found that i.v. 
injection of HUVECs had no signifi  cant (P = 0.47) eff  ect on 
KS tumorigenesis.
Our in vivo tracking results (Fig. 1) suggested that there 
is a signifi  cant reduction (P < 0.001) of the number of MSCs 
at the tumor site over the fi  rst 7 d. Therefore, we reasoned 
that multiple i.v. dosages of human MSCs could potentially 
augment the observed inhibition of KS tumorigenesis. 
  Consistent with this hypothesis, i.v. administration of 4 × 106 
human MSCs on days 0, 3, and 10 signifi  cantly (P < 0.001) 
augmented the in vivo inhibition of KS tumor growth when 
compared with a single dose of human MSCs (Fig. 2 E). In 
contrast, as seen in Fig. 2 E, multiple dosages of HUVECs 
had no signifi  cant eff  ect (P = 0.79) on KS tumorigenesis.
In the aforementioned experiments, MSCs were rou-
tinely injected on the same day that KS tumors were initiated. 
Because tumor establishment and subsequent tumor growth 
are distinct biological processes, we sought to determine 
whether human MSCs exerted similar antitumorigenic 
  eff  ects in animals with preestablished KS tumors. To test 
this, 3 × 106 KS cells were inoculated in the right fl  ank on 
day 0. Palpable tumors were appreciated in all animals by 
day 7. A subset of   animals was then treated with 3 × 106 
human MSCs on days 7, 13, and 17. 4 d after i.v. injection, 
CM-DiI–labeled human MSCs were identifi  ed  diff  usely 
throughout these preexisting tumors (unpublished data). 
  Serial analysis of these animals for >1 mo after tumor im-
plantation demonstrated that human MSCs also signifi  cantly 
inhibited KS tumor growth (P < 0.05) in animals with pre-
established tumors (Fig. 2 F).
Figure 1.  i.v. administered human MSCs home to KS tumors in vivo. 
Human MSCs were labeled with both superparamagnetic iron nanopar-
ticles and the red fl  uorochrome CM-Dil. Where indicated, 4 × 106 labeled 
MSCs were injected into the tail vein of an athymic nude mouse. On the 
same day, 5 × 106 KS cells were injected subcutaneously into the poste-
rior right fl  ank. (A) MRI imaging reveals that as early as 2 d after i.v. injec-
tion, iron-labeled MSCs can be identifi  ed within the KS tumors, as 
indicated by the signal void created by the iron-containing MSCs within 
the KS tumor (arrows). Cells are seen prominently within the body of the 
tumor on day 4 (arrow). By day 7 after cell injection, a minimal signal void 
is observed at the periphery of a tumor (arrow). (B) On day 2, MSCs are 
diffusely distributed within the tumor, as indicated by a low power epi-
fl  uorescence image superimposed on a phase-contrast photomicrograph. 
(C) High power epifl  uorescence image of a single red CM-DiI–labeled 
human MSC residing within a day 4 KS tumor. Cell nuclei are stained 
  using a blue fl  uorescent DAPI counterstain. (D) Multiple CM-DiI–labeled 
MSCs within a day 4 KS tumor surround a relatively acellular, circular 
necrotic area within the tumor (arrows).1238  ANTITUMORIGENIC EFFECTS OF MESENCHYMAL STEM CELLS | Khakoo et al.
Coculture of human MSCs with KS cells inhibits activation 
of Akt within KS cells in a contact-dependent manner
To understand the mechanism of the in vivo inhibition of KS 
tumor growth by i.v. injected MSCs, we performed a series 
of KS cell/MSC coculture experiments. In normal growth 
media, KS cell proliferation was not aff  ected by coculturing 
with MSCs (Fig. 3 A). Similarly, coculture of MSCs with KS 
cells had no eff   ect on vascular endothelial growth factor 
(VEGF) promoter activity within KS cells or overall VEGF 
secretion by KS cells (unpublished data). Because in vitro 
culture conditions do not faithfully reproduce the tumor mi-
croenvironment (35, 36), we asked whether in vitro KS pro-
liferation might be altered by MSCs under conditions of 
diminished nutrient supply. When KS cells were cultured in-
dependently of MSCs, there was no diff  erence in the growth 
rate of these cells in full growth media when compared with 
Figure 2.  i.v. administered MSCs inhibit KS tumorigenesis in vivo. 
(A) Representative tumors on day 23 in athymic nude mice receiving no 
treatment (KS) or receiving a single i.v. dose of 4 × 106 MSCs (KS + MSC). 
(B) On day 0, 5 × 106 KS cells were injected subcutaneously into the pos-
terior right fl  ank of each mouse alone (white bars) or in conjunction with 
i.v. administration of 4 × 106 human MSCs (black bars). Tumor growth and 
progression were monitored by biweekly caliper assessment (*, P < 0.005 
on day 29; n = 4 per group). Data shown is from one experiment that is 
representative of results from three similar experiments. (C) Individual 
tumor growth curves from mice receiving a single dose of i.v. MSCs (cir-
cles) compared with growth curves from untreated animals (squares). 
(D) Similar design as in B except that animals received KS cells alone (white 
bars) or, on day 0, the simultaneous i.v. delivery of 4 × 106 HUVECs (black 
bars; P value is NS at day 26; n = 6 for each group). (E) Reduction in 
tumor volume for animals receiving multiple doses (+ + +) of 4 × 106 
MSCs i.v. on days 0, 3, and 10 versus a single dose (+) of i.v. MSCs on 
day 0 (*, P < 0.005; n = 6 per group; single dose of MSCs vs. untreated 
animals; **, P < 0.001; n = 6 per group; single dose of MSC treatment vs. 
multiple dosages of MSC treatment). In contrast, animals receiving mul-
tiple doses of 4 × 106 HUVECS i.v. on days 0, 3, and 10 were indistin-
guishable from animals receiving KS cells alone. Data is expressed as the 
percentage of day 23 tumor volume with animals that received KS cells 
alone set at 100%. (F) Mean tumor volume in animals with preexisting 
tumors. All animals had palpable, well-established tumors before the ad-
ministration of the fi  rst dosage of MSCs and were randomized to receive 
saline infusion or multiple doses of 4 × 106 MSCs i.v. on days 7, 13, and 
17 (*, P < 0.05; n = 6 in the treated group; n = 4 in the untreated 
group). Error bars represent SEM.JEM VOL. 203, May 15, 2006  1239
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growth in media with moderately reduced extracellular 
  glucose (Fig. 3 B). In contrast, as seen in Fig. 3 B, the growth 
of KS cells cocultured with MSCs was signifi  cantly reduced 
when grown in the presence of media with lower glucose. 
Similar results were obtained in media containing reduced 
FCS (unpublished data). Importantly, when MSCs and KS 
cells were cocultured but separated by a transwell membrane, 
which allows the exchange of soluble factors but prevents 
  direct cell–cell contact, KS proliferation was not aff  ected by 
altering glucose levels (Fig. 3 B).
To further explore the eff  ect of human MSCs on KS 
cells, we next examined the eff  ects of MSCs on activation of 
the protein kinase Akt, which is a critical mediator of KS 
  tumor growth and survival. Inhibition of Akt activity by the 
pharmacologic blockade of the upstream activator PI3 kinase 
or genetic suppression by the expression of a dominant-neg-
ative Akt construct has been previously shown to result in the 
profound inhibition of KS cells (37). These results suggest an 
important physiologic link between Akt activation and KS 
cell survival. In addition, in a mouse KS model, pharmaco-
logical inhibition of Akt has been shown to inhibit tumori-
genesis (38). Given the importance of this pathway to KS 
biology, we asked whether direct coculture with MSCs in-
hibited Akt activation in KS cells.
To test this hypothesis, we made use of the fact that after 
direct coculture, the KS cell population could be repurifi  ed 
by fl  ow cytometry based on both size and cell surface charac-
teristics of KS cells (Fig. 3 C). As demonstrated in Fig. 3 D, 
when KS cells were repurifi  ed after direct MSC coculture, 
we observed a potent decrease in the levels of Akt phosphor-
ylation (serine position 473). Similar results were obtained 
using an antibody that recognizes phosphothreonine at posi-
tion 308 of Akt (unpublished data). In contrast, as seen in Fig. 
3 E, total Akt levels were unaff  ected by coculture. Notably, 
the inhibitory eff  ect on Akt phosphorylation was not seen 
when KS cells were directly cocultured with mature endo-
thelial cells (Fig. S4, available at http://www.jem.org/cgi/
content/full/jem.20051021/DC1). Similar to the eff  ects of 
MSCs on KS proliferation, when MSCs and KS cells were 
cocultured but separated by a transwell membrane, the inhi-
bition of Akt phosphorylation within KS cells was not ob-
served (Fig. 3 F). These eff  ects appeared specifi  c because 
the direct coculture of MSCs and KS cells did not alter the 
levels of either phosphorylated ERK1/2 or phosphorylated 
MEK1/2 within KS cells (Fig. 3 G and Fig. S5). Together, 
these fi  ndings demonstrate that MSCs specifi  cally inhibited 
Akt activation within KS cells and that this interaction re-
quires direct cell contact.
Several groups have observed that the immunosuppres-
sive eff  ects of human MSCs are mediated by the eff  ects of 
MSCs on antigen-presenting cells (39, 40) and that these 
  eff  ects require (39) direct cell contact or are potentiated by 
direct cell contact (40). Collectively with our fi  ndings, this 
suggests a potent biological activity of human MSCs aff  ecting 
a variety of cell types occurring only when the two cell types 
are in close contact. Because adhesive cell–cell interactions 
are mediated by cadherin proteins and because the loss of 
  expression of the cell surface protein E-cadherin promotes a 
more aggressive phenotype of transformed cells in vitro and 
in vivo (41–44), we asked whether treatment with a neutral-
izing antibody against E-cadherin could block the eff  ect of 
MSCs on KS cells. As noted in Fig. 3 H, the addition of a 
neutralizing antibody to E-cadherin to MSC/KS cocultures 
markedly attenuated the inhibitory eff  ects of MSCs on Akt 
activation within KS cells (compare with Fig. 3 D). We ob-
served no eff  ect on Akt activity in these cultures after the 
  addition of an isotype IgG control antibody. These fi  ndings 
further support the requirement of direct cell–cell contact in 
mediating the eff  ects of MSCs on target cells.
Human MSCs inhibit Akt activation within other primary 
cell lines but not within other tumor cell lines
To further explore the eff  ects of MSCs on target cell Akt ac-
tivation within cell types other than KS cells, we directly co-
cultured human MSCs with two diff  erent primary cell lines 
and with two diff  erent tumor cell lines. Direct coculture of 
human MSCs with either a primary endothelial cell culture 
(Fig. 4 A) or with primary neonatal cardiac myocytes (Fig. 
4 B) substantially inhibited phospho-Akt levels without 
  aff  ecting total Akt levels. The latter result is of particular in-
terest given the observed inhibition of pathological cardiac 
hypertrophy in animals treated with MSCs after myocardial 
infarction (45, 46) and the well-established link between Akt 
activation and hypertrophy in cardiac myocytes (47, 48). As 
previously seen in KS/MSC cocultures, transwell culture of 
human MSCs with primary endothelial cells had no eff  ect on 
phospho-Akt levels within the endothelial cells (unpublished 
data). Similarly, treatment of MSC/endothelial cell cocul-
tures with a neutralizing antibody against E-cadherin abro-
gated the inhibition of Akt activation within endothelial cells 
(Fig. 4 C). In contrast to these eff  ects, incubation of MSCs 
with the prostate tumor cell line PC-3 or the breast cancer 
tumor line MCF-7 had no eff   ect on phospho-Akt levels 
within PC-3 cells (Fig. 4 D) or MCF-7 cells (not depicted).
Antitumorigenic effect of human MSCs requires 
the inhibition of Akt activation within tumor target cells
We then asked whether the in vivo eff  ects of MSCs on KS 
tumorigenesis are linked to the inactivation of Akt within 
KS target cells. 2 d after the simultaneous i.v. injection of 
MSCs and subcutaneous implantation of KS tumors, tumors 
were harvested and lysed. Western blot analysis revealed 
that compared with tumors from animals that received no 
human MSCs, KS tumors from animals receiving MSCs had 
decreased levels of phosphorylated Akt (Fig. 5 A).  To assess 
whether known Akt targets were also reduced in the KS tu-
mors, we analyzed the phospho– to total GSK-3β ratio from 
tumor lysates in control animals as well as those animals re-
ceiving MSCs. Consistent with the observed reduction in 
phospho-Akt, we noted an  25% reduction in phospho–
GSK-3β activity in animals receiving coadministered MSCs 
(phospho–GSK-3β/total GSK-3β ratio in arbitrary units: 1240  ANTITUMORIGENIC EFFECTS OF MESENCHYMAL STEM CELLS | Khakoo et al.
Figure 3.  MSCs induce a contact-dependent inhibition of Akt 
activation. (A) The proliferation of KS cells is not affected by direct co-
culture with MSCs in full growth media. Various ratios of KS cells to 
MSCs are shown. (B) Change in cell number over 48 h of KS cells grown 
in the presence or absence of MSCs and cultured with either 2 g/liter (+) 
or 1 g/liter (−) glucose. KS cell growth was assessed with MSCs in a co-
culture format as well as in a transwell format, which prevented KS–MSC 
cell contact. *, P < 0.005. (C) KS cells were cocultured with MSCs for 18 h 
in a 1:10 (MSC/KS cell) ratio. Flow cytometric forward scatter and side 
scatter analysis of KS cell–MSC cocultures demonstrating the separation 
of viable, larger KS cells from human MSCs. Cell surface staining for 
Stro-1, a marker present on most human MSCs but not on KS cells, was 
used to further gate out MSCs (not depicted). (D) Levels of phosphory-
lated Akt (Ser473) in KS cells directly cocultured with MSCs (KS + MSC) 
were reduced compared with levels of phosphorylated Akt in KS cells 
alone (KS). (E) Total Akt levels within KS cells are not affected by cocul-
ture with MSCs. (F) No difference in phosphorylated Akt levels were 
seen in KS cells cocultured with MSCs but separated by a transwell 
(KS + MSC) compared with KS cells alone (KS). (G) Levels of phosphory-
lated ERK1 and 2 (Thr202 and Tyr204 combined) were not signifi  cantly 
affected by direct coculture with MSCs (KS + MSC) compared with KS 
cells alone. (H) KS cells were directly cocultured with MSCs for 18 h in a 
1:10 (MSC/KS cell) ratio in the presence of a blocking antibody against 
E-cadherin. The inhibitory effects of MSCs on Akt phosphorylation in 
KS cells are markedly reduced in the presence of a neutralizing antibody 
against E-cadherin (compare with D). All of the aforementioned results 
are representative of at least three similar experiments. Error bars 
represent SEM.JEM VOL. 203, May 15, 2006  1241
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0.477 ± 0.05 for KS alone vs. 0.346 ± 0.06 for KS + MSC 
tumors; n = 7 per group; P < 0.01). Mirroring our previous 
in vitro results, we saw no substantial diff   erence in the 
  phospho- to total ERK1 and 2 ratio between lysates from 
MSC-treated and untreated animals. Immunohistochemical 
analysis demonstrated that in KS tumors, levels of phospho-
Akt were noticeably reduced in the vicinity of incorporated 
MSCs (Fig. 5 B).
Figure 4.  Akt activation within cardiac myocytes and mature en-
dothelial cells but not prostate tumor cells is inhibited by coculture 
with MSCs. Neonatal cardiac myocytes (CM), HUVECs, or PC-3 cells were 
cocultured with human MSCs at a ratio of 1:10 (MSC/target cell). 18 h 
after coculture, phospho-Akt levels within cardiac myocytes, HUVECs, or 
PC-3 cells were assessed by fl  ow cytometry and compared with phospho-
Akt levels with cardiac myocytes, HUVECs, or PC-3 cells cultured alone. 
(A) In MSC/HUVEC cocultures, HUVECs were repurifi  ed using an antibody 
against human CD31 (left). Levels of phosphorylated Akt (Ser473) in 
  HUVECs directly cocultured with MSCs (HUVEC + MSC) are decreased com-
pared with HUVECs cultured alone (middle). Total Akt levels in HUVECS are 
unchanged in the presence of MSCs compared with HUVECs cultured 
alone (right). (B) In MSC/cardiac myocyte cocultures, MSCs were gated 
out using an antibody against human CD44, which reacts with human 
MSCs but not mouse neonatal cardiac myocytes (left). Levels of phos-
phorylated Akt (Ser473) in cardiac myocytes directly cocultured with 
MSCs (CM + MSC) are decreased compared with cardiac myocytes cul-
tured alone (CM; middle). Total Akt levels in neonatal cardiac myocytes 
are unchanged in the presence of MSCs compared with cardiac myocytes 
cultured alone (right). (C) MSCs were cocultured with HUVECs for 18 h in 
a 1:10 (MSC/HUVEC) cell ratio in the presence of a blocking antibody 
against E-cadherin or an IgG control antibody. The inhibitory effects of 
MSCs on Akt phosphorylation in KS cells seen in the presence of control 
IgG antibody (left) are abrogated in the presence of a neutralizing anti-
body against E-cadherin (right). (D) PC-3 cells were cocultured with MSCs 
for 18 h in a 1:10 (MSC/PC-3) cell ratio. Cell surface staining for prostate 
cell surface antigen was used to repurify PC-3 cells from MSCs after co-
culture (not depicted). Levels of phosphorylated Akt (Ser473) in PC-3 cells 
directly cocultured with MSCs (PC-3 + MSC) were unchanged compared 
with levels of phosphorylated Akt in PC-3 cells alone (PC-3). In all of the 
aforementioned experiments, results shown are representative of at least 
three similar experiments.1242  ANTITUMORIGENIC EFFECTS OF MESENCHYMAL STEM CELLS | Khakoo et al.
Given the central role of Akt in cell survival and prolifer-
ation, particularly in KS cells, we next examined the eff  ect of 
MSCs on early necrosis within KS tumors. Strikingly, we saw 
a profound increase in the area of tumor necrosis 7 d after KS 
tumor implantation and i.v. MSC injection (Fig. 5 C). Using 
morphometric analysis on multiple sections of KS tumors 
from treated and untreated animals, we observed a greater 
than twofold increase in the percentage of tumor that was 
necrotic in animals treated with MSCs (Fig. 5 D). Similarly, 
in animals with tumors established before the infusion of 
MSCs, histological analysis of KS tumors 10 d after the fi  rst 
treatment demonstrated that the MSC-treated animals had 
smaller nests of viable tumor cells along with a substantially 
augmented host infl  ammatory response characterized by a 
profound neutrophilic infi  ltrate (Fig. S6, available at http://
www.jem.org/cgi/content/full/jem.20051921/DC1).
To further explore the hypothesis that the eff  ect  of 
MSCs on in vivo tumorigenesis depends on Akt inactiva-
tion with tumor target cells, we examined the eff  ects of 
MSCs on PC-3 tumorigenesis in vivo. As noted previously, 
Akt activity in this tumor cell type was not responsive to 
MSC inhibition. To test the eff  ects of MSC infusion on 
PC-3 tumor growth, we implanted 5 × 106 PC-3 cells sub-
cutaneously in athymic nude mice. Half of these mice re-
ceived 4 × 106 MSCs i.v. on days 0, 3, and 10 after PC-3 
tumor implantation, whereas the other half received no fur-
ther treatment. In contrast to the potent eff  ect on KS tu-
morigenesis we observed in animals that received multiple 
dosages of MSCs i.v., treatment with MSCs had no eff  ect 
on PC-3 tumorigenesis in vivo (Fig. 5 E).
Finally, we asked whether the inhibition of Akt activa-
tion was necessary for MSCs to exert their antitumorigenic 
eff  ect in KS cells. To test this hypothesis, KS cells were trans-
fected with either a constitutively active myristoylated Akt 
construct (myrAkt; reference 49) or an empty vector control 
(vector). Tumors from these transfected cells (KS/myrAkt or 
KS/vector) were implanted 24 h later, and, simultaneously, 
half of the animals were treated with a single i.v. dosage of 
4 × 106 MSCs. As seen in Fig. 5 F, animals receiving KS/
myrAkt cells had larger tumors compared with animals re-
ceiving KS/vector cells. Consistent with our prior fi  ndings, 
a potent inhibitory MSC eff  ect was once again seen in ani-
mals with tumors derived from KS/vector cells. However, 
we saw no diff  erence in tumor growth with or without MSCs 
when the KS tumors were engineered to express a constitu-
tively active form of Akt.
DISCUSSION
The aforementioned studies were intended to understand 
the role of MSCs (the stromal progenitor cell population 
within the bone marrow) in promoting or inhibiting the 
growth of a highly angiogenic tumor. As early as 48 h after 
i.v. injection, MSCs could be observed homing in large 
numbers to areas of KS tumorigenesis. Our fi  nding that hu-
man MSCs home to subcutaneously implanted KS tumors in 
vitro is consistent with and further strengthens the argument 
that i.v. delivered human MSCs specifi  cally migrate to sites 
of active tumorigenesis in vivo. In this regard, it has previ-
ously been shown that i.v. injected MSCs can incorporate 
into tumors within the lung (21). These previous results may 
need to be interpreted with some caution because we also 
fi  nd that in our model, some MSCs incorporated into the 
pulmonary microvasculature. As such, MSCs within the pul-
monary vasculature may not necessarily represent the direct 
evidence of tumor-specifi  c homing. In addition to fi  nding 
cells diff  usely scattered throughout the tumor early after in-
jection, we fi  nd cells predominantly within the lung as well 
as within the reticuloendothelial system, with some cells also 
seen within the bone marrow. Interestingly, we fi  nd no evi-
dence of MSCs within other highly vascular organs such as 
the kidney, heart, and brain. Our observations of the tissue 
distribution of i.v. injected MSCs are similar to observations 
of MSC distribution after i.v. injection into animals after 
myocardial infarction (16). In this previous study, cells were 
found in the lung, liver, and spleen as well as within the bor-
der zone of the infarcted heart. Collectively, these fi  ndings 
suggest that in addition to the reticuloendothelial network, 
MSCs may have the ability to potentially home to areas of 
tissue ischemia or active angiogenesis such as the infarcted 
heart or the tumor microenvironment.
Unexpectedly, we observed a potent inhibitory eff  ect on 
KS in vivo mediated by human MSCs administered i.v. These 
eff  ects could be detected early after tumor implantation and 
cell injection and could be augmented with multiple dosages 
of MSCs. The inhibitory eff  ects of MSC infusion were dem-
onstrated when MSC infusion began at the time of tumor 
implantation or when MSCs were used to treat preexisting 
KS tumors. It is theoretically possible that the delivery of hu-
man cells into a mouse inoculated with a human KS tumor 
might potentiate a nonspecifi  c xenogenic immune response 
within the mouse that may inhibit in vivo tumorigenesis. 
  Arguing against this possibility is the lack of eff  ect seen when 
mice are treated with HUVECs, which, like MSCs, are pri-
mary human cells that express similar levels of MHC class I 
and II on their surface. Furthermore, the immune response of 
the athymic nude mouse, which is mediated primarily by NK 
cells, is much less vigorous to xenogenic stimuli.
Several of our observations support the argument that hu-
man MSCs exert their antitumorigenic eff  ects on KS tumors 
through direct, local eff  ects on KS cells. In vitro, we see the 
inhibition of Akt phosphorylation only when the cells are in 
direct contact. In vivo, we observe very similar eff  ects on 
cell signaling in tumor lysates of animals that received MSCs. 
Furthermore, using indirect immunofl   uorescence, we ob-
serve the inhibition of Akt activation in the local micro-
environment surrounding the MSCs within KS tumors. 
Collectively with other studies demonstrating inhibitory ef-
fects on dendritic cells (39) and T cells (40), our fi  ndings sug-
gest that MSCs can communicate with a variety of cell types 
and prevent cellular activation in a contact-dependent 
manner. We extend this work further by demonstrating that 
the blockade of the adhesion molecule E-cadherin abrogates JEM VOL. 203, May 15, 2006  1243
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Figure 5.  In vivo antitumorigenic effects of MSCs depend on the 
inactivation of Akt in target tumor cells. (A) Western blot analysis 
of lysates from four separate tumors harvested on day 2 demonstrates 
a reduction of phosphorylated Akt (Ser473) in MSC-treated animals. 
Total Akt levels within tumor lysates are unaffected by i.v. MSC 
injection. (B) Confocal fl  uorescence microscopy reveals that in areas 
surrounding MSCs (red CM-Dil–labeled cell, right), there is diminished 
phospho-Akt staining (green) compared with an area in the same KS 
tumor (left) that lacks incorporated MSCs. Cell nuclei are indicated with 
blue fl  uorescent DAPI nuclear counterstain. (C) Representative images 
of day 7 tumors stained with hematoxylin and eosin revealing that 
tumors from animals receiving i.v. MSCs (right) have more pronounced 
areas of central necrosis (arrows) compared with tumors from animals 
receiving no cells (left). (D) Quantitative blinded morphometry of mul-
tiple sections in KS tumors demonstrate a greater than twofold in-
crease in the area of necrosis within the tumors in those animals 
receiving MSCs (KS + MSC) compared with tumors from untreated 
animals (KS). *, P < 0.01; n = 5 mice for each group, with at least fi  ve 
random sections per tumor analyzed. (E) On day 0, 5 × 106 PC-3 cells 
were injected subcutaneously into the posterior right fl  ank of each 
mouse alone (white bars) or in conjunction with i.v. administration of 
4 × 106 human MSCs (black bars). i.v. MSC treatment was repeated on 
days 3 and 10. Tumor growth and progression were monitored by bi-
weekly caliper assessment (P value is NS on day 31; n = 5 per group). 
(F) On day 0, 5 × 106 KS/vector or KS/myrAkt cells were injected subcu-
taneously into the posterior right fl  ank of each mouse alone or in con-
junction with i.v. administration of 4 × 106 human MSCs. Data are 
expressed as the percentage of day 23 tumor volume compared with 
animals that received tumors derived from KS/vector cells alone (n = 4 
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the inhibitory eff  ects of MSCs on Akt activation within tar-
get cells. Interestingly, the in vivo reduction of phospho-Akt 
levels within KS tumors appeared to extend to tumor cells 
that are not in direct contact with incorporated MSCs (Fig. 
5 B), suggesting a potential role for paracrine signaling that is 
initiated after MSC–target cell interaction. The precise mo-
lecular details by which contact with MSCs results in the in-
hibition of Akt activation will be the focus of future work.
Interestingly, we observed that tumors from animals 
treated with MSCs had a greater proportion of tumor stroma 
compared with tumors from untreated animals (Fig. S6). The 
increased fi  brous tissue seen within tumors from MSC-treated 
animals may represent a host response to enhanced tumor 
necrosis mediated by MSCs. On the other hand, MSCs are 
known precursors of stromal cells, which generate the extra-
cellular matrix supporting hematopoiesis within the bone 
marrow microenvironment (50). Therefore, it is possible that 
within the tumor microenvironment, stromal components 
derived from MSCs may play a role in inhibiting tumor 
growth. Detailed characterization of the properties of MSCs 
after tumor engraftment will be addressed in future studies.
In conclusion, we show that MSCs, a subpopulation of 
adult bone marrow–derived stem cells, exhibit potent antitu-
mor eff  ects in a model of KS. This eff  ect is mediated by direct 
cell contact leading to the inhibition of Akt activation within 
KS cells. These fi  ndings contrast with recent studies demon-
strating that certain stem cell populations can promote or 
give rise to neoplastic growth (6, 28, 51). Our fi  ndings are 
particularly surprising in light of the demonstrated proangio-
genic eff  ects of MSCs in ischemic tissue (29, 52, 53). Further-
more, our fi  ndings suggest that MSCs represent a unique 
stromal cell population that, in contrast to the reported eff  ects 
of normal or carcinoma-associated fi  broblasts, can directly 
inhibit tumorigenesis. In light of recent studies demonstrat-
ing that infused MSCs may have a therapeutic role in pre-
venting graft versus host disease in cancer patients after bone 
marrow transplantation (54–56), the antitumorigenic eff  ects 
of MSCs are particularly reassuring. We speculate that the 
ability of MSCs to inhibit Akt signaling may also be an im-
portant aspect of the endogenous function of MSCs within 
the normal bone marrow microenvironment. Interestingly, 
antitumorigenic properties have been previously observed in 
other microenvironments that support regulated progenitor 
cell growth and proliferation, such as seen in normal mouse 
blastocysts (57) or within the cambial layer of tobacco plants 
(58). Finally, although KS tumors are unique malignancies 
with an unclear cellular origin, our results suggest at least the 
potential to exploit the biology of MSCs to treat a subset of 
human malignancies.
MATERIALS AND METHODS
Primary cells and cell lines. First passage human MSCs obtained from bone 
marrow aspirates of healthy young donors were purchased from Cambrex. 
We obtained and pooled MSCs from four diff  erent healthy young donors 
(two male and two female). MSCs were cultured in MSC growth media 
(MSCGM; Cambrex). Media was changed every 3 d, and cells were split 
when 70% confl  uence was achieved. MSCs were used at passage 3–7 for all 
experiments. HUVECs were also obtained commercially (Cambrex) and 
were cultured in EGM endothelial cell media (Cambrex). The KS cell line 
KSIMM was provided by A. Albini (Istituto Nazionale per la Ricerca sul 
Cancro, Genoa, Italy; reference 59) and was cultured except where indicated 
in RPMI + 10% heat-inactivated FCS. All coculture experiments were also 
performed in this media. The human prostate cancer cell line PC-3 and the 
human breast cancer line MCF-7 were purchased from American Type Cul-
ture Collection and were cultured in Ham’s F-12K medium with 2 mM 
l-glutamine + 10% heat-inactivated FCS. Neonatal mouse cardiac   myocytes 
were isolated and cultured as previously described (60).
Cell proliferation measurement. For quantifi  cation of KS cells in cocul-
ture experiments, KS cells were incubated with CFDA-SE green fl  uorescent 
label (Invitrogen) at a fi  nal concentration of 5 μM for 15 min and were vig-
orously washed before coculture. 24 or 48 h after coincubation with human 
MSCs, KS cell proliferation was quantifi  ed using low power epifl  uorescence 
microscopy and a hemocytometer (Bright Line; Hausser Scientifi  c). Prolif-
eration experiments were performed with MSCs that were directly cocul-
tured with KS cells or with MSCs separated from KS cells by a transwell 
membrane with a 0.4-μm pore size (Corning, Inc.). Proliferation experi-
ments were performed in RPMI-1640 media with varying concentrations of 
FCS ranging from 1 to 10% and either low (1 g/liter) or normal (2 g/liter) 
glucose concentrations. Proliferation data represent the mean ± SD of 
  triplicate experiments.
Flow cytometry. KSIMM cells that were cocultured with MSCs or 
HUVECs were harvested 18 h after coculture. Cells were detached with 
1 mM EDTA and counted. Cells were prepared for intracellular staining by 
fi  xing them in 1% formaldehyde for 10 min at 37°C followed by permeabili-
zation in 90% ice-cold methanol for 30 min. 0.5 × 106 aliquots of cells were 
washed twice in PBS with 0.5% BSA. Appropriate antibodies were aliquoted 
into each tube and incubated at room temperature for 30 min. Secondary 
antibodies conjugated to PE or FITC (Jackson ImmunoResearch Laborato-
ries) were used for the detection of those primary antibodies that were un-
conjugated. Cocultured cells were also stained with FITC-conjugated Stro-1 
antibody (R&D Systems), FITC-conjugated CD31 antibody (BD Biosci-
ences), FITC-conjugated CD44 antibody (BD Biosciences), human prostate 
cell surface antigen antibody (Chemicon), or FITC-conjugated p185/HER-2 
antibody (Biosource International), which enables gating of the MSCs, 
HUVECS, cardiac myocytes, PC-3 cells, or MCF-7 cells, respectively, and 
subsequent purifi  cation of the KS cells, HUVECs, cardiac myocytes, PC-3 
cells, or MCF-7 cells alone. Cells were washed twice in PBS + 0.5% BSA, 
and samples were subsequently analyzed using a fl  ow cytometer   (FACScalibur; 
BD Biosciences). Antibodies to phospho-Akt (Ser473 and Thr308), Akt, 
phospho-ERK1/2 (Thr202/Tyr204), and phospho-MEK1/2(Ser217/221) 
were obtained from Cell Signaling. Appropriate isotype controls were 
used for each antibody as a control for nonspecifi  c antibody binding. 
FlowJo software (Tree Star, Inc.) was used to analyze the raw fl  uorescence-
activated cell-sorting data and plot histograms.
Disruption of E-cadherin–mediated interactions in MSC cocul-
tures. For determination of the role of E-cadherin–mediated interactions in 
KS/MSC or HUVEC/MSC cocultures, a mouse anti–human neutralizing 
antibody to E-cadherin (Abcam) or an IgG1 isotype control antibody was 
added at the onset of coculture at a dilution of 1:25. Cocultures were incu-
bated for 18 h in the presence of the E-cadherin neutralizing antibody or 
IgG1 isotype control, and Akt activation in KS cells or HUVECs was deter-
mined by fl  ow cytometry after repurifi  cation using techniques described in 
the previous paragraph.
Animal model. National Institutes of Health Swiss male athymic nude 
mice (nu/nu) were obtained from the National Cancer Institute (NCI). 
  Animals from age 6 to 10 wk (with no more than a 2-wk spread in a single 
experiment) were used for tumor formation and inhibition experiments. 
Animals were housed in micro-isolator cages under sterile conditions and 
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Lighting, temperature, and humidity were controlled centrally and recorded 
daily. Animals were injected with 5 × 106 KS cells (suspended in 100 μl 
PBS) subcutaneously into the posterior fl  anks. Treatment with MSCs or 
HUVECs was initiated simultaneously or in animals with preestablished tu-
mors by i.v. tail vein injection. In some experiments, mice were given addi-
tional doses of MSCs or HUVECs by tail vein injection. Tumors became 
visible and palpable at day 2 after KS cell inoculation. Tumor growth and 
progression were monitored by biweekly measurements of tumors with 
  calipers. All mouse experiments were performed using methods described in 
detailed protocols approved by the Animal Care and Use Committee at the 
National Heart, Lung, and Blood Institute (NHLBI) and by the Institutional 
Animal Care and Use Committee at the University of Maryland.
Transfection of KS cells with constitutively active Akt construct. 
The myristoylated Akt plasmid (myrAkt) has been previously described (49) 
and was provided by M. Greenberg (Children’s Hospital, Boston, MA). 
KSIMM cells were transfected using the Nucleofector transfection system 
(Amaxa Biosystems) with myristoylated Akt (KS/myrAkt) or with empty 
vector (KS/vector). Using a GFP expression vector, we could demonstrate 
that this strategy routinely resulted in 80–90% transfection effi   ciencies. 24 h 
after transfection, KS cells were harvested and washed, and animals were in-
jected with 5 × 106 transfected KS cells (suspended in 100 μL PBS) subcu-
taneously into the posterior fl  anks.
Multiplex cytokine measurements. For measurements of cytokine levels 
from KS cells, MSCs, or HUVECs, we harvested conditioned media 48 h 
after initial culture, spun down the media to eliminate any cellular material, 
and snap-froze samples that were stored at −80°C until analyzed. For multi-
plex cytokine experiments, we used commercially available fl  uorophore-
conjugated bead sets for the following cytokines: ENA-78, G-CSF, IL-1α, 
IL-6, IL-8, MCP-1, and VEGF-A (all from R&D Systems). Beads were in-
cubated according to the manufacturer’s instructions, and data were acquired 
using a dual-laser instrument (Luminex 100; Luminex Corp.).
Iron labeling of MSCs and in vivo imaging. To label MSCs with su-
perparamagnetic iron oxide particles, MSCs were grown to 70% confl  uence 
in MSCGM. MSCs were then washed vigorously and resuspended in a min-
imal volume of serum-free RPMI-1640 medium (Biosource International). 
Complexing of polycationic transfection agents to ferumoxides to promote 
cellular iron uptake was performed as previously described (33). In brief, we 
used a commercially available ferumoxide suspension (Feridex IV; Berlex 
Laboratories) in combination with protamine sulfate (American Pharmaceu-
ticals Partner), which was supplied at 10 mg/ml. Ferumoxides were diluted 
to a fi  nal concentration of 100 μg/ml in RPMI-1640 and were combined in 
a mixing fl  ask with protamine sulfate at a fi  nal concentration of 4 μg/ml. 
The solution containing ferumoxides and protamine sulfate was mixed for 
5–10 min with intermittent hand shakings. After 5–10 min, an equal volume 
of the solution containing FE-Pro complexes was added to the existing me-
dia in the adherent cell culture. After incubation for 2–3 h, an equal volume 
of MSCGM was added to the cells for a fi  nal concentration of 25 μg feru-
moxides/ml of medium. The cell suspension was then incubated overnight 
at 37°C. Before injection, cells were vigorously washed twice with PBS plus 
heparin at 10 U/ml and then twice with ice-cold PBS before being har-
vested for i.v. injection. Labeling effi   ciency was >90% and was confi  rmed 
by Prussian blue staining of cytospun cell preparations.
MRI was performed using a horizontal bore imaging system (7.0T; 
Bruker) with 39-G/cm gradients. Mice were anesthetized with 1.5% isofl  u-
rane and positioned in a 35-mm Bruker volume coil with physiological 
monitoring. A water-fi  lled glass tube was positioned adjacent to the tumor 
site in some mice with small tumors to assist identifying the tumor location. 
Two-dimensional steady-state gradient echo images were acquired with re-
spiratory gating in coronal and axial planes. Coronal planes were acquired 
through the body to assess the liver, spleen, marrow, and tumor. Axial planes 
were acquired to assess the tumor site in detail. In coronal images, imaging 
parameters were as follows: repetition time/echo time = 550/5.0 ms; nine 
slices; slice thickness of 0.35 mm; fi  eld of view of 5.0 × 3.0 cm2; 512 × 256 
matrix; four excitations. For axial images, parameters were as follows: repeti-
tion time/echo time = 400/5.0 ms; six slices; slice thickness of 0.35 mm; 
fi  eld of view of 2.5 × 3.0 cm2; matrix either of 256 × 256 or 384 × 384 
zero-fi  lled to 512 × 512; four to six excitations.
Western blotting. Day 2 tumors were harvested and lysed in lysis buff  er 
(0.5% Triton X-100 in PBS, pH 7.4) with protease inhibitors (complete 
minileupeptin, aprotinin, and Pefabloc; Boehringer). Protein quantifi  cation 
was performed by bicinchoninic acid assay, and equal amounts of protein 
  lysate were resolved on SDS-PAGE 4–12% gels. Transfer to nitrocellulose 
membranes was performed in transfer buff  er (12 mM Tris base, 96 mM gly-
cine, pH 8.3, and 15% methanol). Membranes were subsequently probed 
with primary antibodies to phospho-Akt (Ser473) and total Akt (Cell Signal-
ing) and detected using enhanced chemiluminescence (GE Healthcare) ac-
cording to the manufacturer’s protocol.
Microscopy and immunofl  uorescence. Slides were visualized using 
wide-fi  eld microscopy (both diff  erential interference contrast and fl  uores-
cence) using an upright microscope (E-1000; Nikon), and images were ac-
quired on a CCD color digital camera (DXM-1200; Nikon) using ACT1 
software (Nikon). To assess the cell localization with higher resolution, im-
ages were obtained with a confocal system (SP1; Leica) equipped with 
UV-Vis lasers (Leica). Images were acquired sequentially using a 351-nm 
  laser line and emission between 420 and 485 nm for DAPI, a 488-nm laser 
line and emission between 490 and 560 nm for FITC, and a 568-nm laser 
line and emission between 575 and 690 nm for DiI. Images were obtained 
with a 63× 1.4 NA plan-Apochromat oil immersion objective (Carl Zeiss 
MicroImaging, Inc.) using identical hardware settings to allow fl  uorescence 
intensity comparisons. Overlay images were assembled, zoomed, and 
cropped using Imaris 4.1 software (Bitplane).
For immunofl  uorescence staining, we harvested tumors on day 2 from 
mice that were killed and immediately perfused with ice-cold saline. Tumor 
samples were immediately embedded in Tissue-Tek optimal cutting tem-
perature (Sakura Finetek), snap-frozen in isopentane immersed in liquid ni-
trogen, and stored at −80°C. Cryostat frozen sections were fi  xed  with 
ice-cold methanol or acetone, blocked for 30 min with 5% goat serum, and 
incubated overnight at 4°C with a rabbit polyclonal antibody against phos-
pho-Akt (Cell Signaling) at a fi  nal dilution of 1:50. To detect evidence of 
MSC diff  erentiation, we used mouse monoclonal antibodies against human 
CD13 (1:25), CD33 (1:25), CD34 (1:25), and myeloperoxidase (1:25; Dako-
Cytomation). After vigorous washing, sections stained with rabbit anti-
bodies were incubated with a goat anti–rabbit IgG fl  uorescein-conjugated 
secondary antibody (Vector Laboratories) at a fi  nal dilution of 1:100 at room 
temperature for 2 h. Antibody detection in sections stained with mouse 
monoclonal antibodies was performed using the MOM Fluorescein kit 
(Vector Laboratories). Sections were then washed and coverslipped in Vecta-
shield with DAPI (Vector Laboratories). Parallel samples were incubated 
with no primary antibody as a specifi  city control. Normal human blood 
smears were used as positive control samples for CD13, CD33, and myelo-
peroxidase staining. MSCs were labeled with the conjugated fl  uorochrome 
Cell Tracker CM-DiI (Invitrogen) before i.v. administration for identifi  ca-
tion in histopathological sections.
Tumor analysis. For measurement of the necrotic area within the tumors, 
tumors were fi  rst harvested and fi  xed in 10% buff  ered formalin. Tumors 
were embedded in paraffi   n, and serial sections were made at 100-μm incre-
ments throughout the tumor. At each level, a section of the tumor was 
stained with hematoxylin and eosin, and a digital low power photomicro-
graph was made. Digital images were imported into MetaMorph software 
v6.1 (Universal Imaging Corp.). The area of necrosis and the total cross-
  sectional tumor area was identifi  ed, traced, and quantifi  ed manually. Measure-
ments were performed after masking the treatment allocation group of the 
given tumor sections. Immunohistochemical staining of KS tumors to deter-
mine the presence of host neutrophils within tumors was performed using 
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1:25. Antibody detection was performed using the Vectastain ABC kit 
(Vector Laboratories).
Quantitative phosphoprotein measurements for GSK-3β and ERK1/2 
were performed using electrochemiluminescence from Meso Scale Discovery. 
Day 2 tumors were isolated and snap-frozen. Tumors were thawed and 
  homogenized by sonication within cell lysis buff  er containing both phospha-
tase and protease inhibitors. Protein concentration was measured using the 
bicinchoninic acid protein assay kit (Pierce Chemical Co.). Equal amounts 
of protein were input into the assays, and duplicate samples were analyzed 
from each tumor lysate in triplicate.
Statistical analyses. Statistical analyses were performed using Excel 
(Microsoft) and Prism 4.0 (GraphPad Software). For tests of comparison, we 
used a two-sample t test. All P values presented are two-tail values.
Online supplemental material. Fig. S1 shows a cytokine profi  le of MSCs 
compared with KS cells and HUVECs. Fig. S2 shows a detailed fl  ow cyto-
metric characterization of MSCs. Fig. S3 displays in vivo MRI showing the 
distribution of iron-labeled MSCs after i.v. injection. Fig. S4 shows that di-
rect coculture of HUVECs with KS cells has no eff  ect on Akt activation in 
KS cells. Fig. S5 shows that coculture of MSCs with KS cells has no eff  ects 
on phospho-MEK1/2 levels within KS cells. Fig. S6 shows the comparison 
of tumors from treated and untreated animals in which tumors were estab-
lished before the administration of MSCs. Online supplemental material is 
available at http://www.jem.org/cgi/content/full/jem.20051921/DC1.
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